Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

Filter results: >>>>
  • Page 1 of 429
  • 1 to 25 of 10710 records
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
MDA-MB-134-VI Cediranib
10.0
VEGFR/cKIT
RTK
-0.9999 0.83082
MDA-MB-134-VI Ceritinib
10.0
ALK
RTK
-0.9992 0.80386
MDA-MB-134-VI Abemaciclib
10.0
CDK4/6
Cell cycle
-0.9986 0.81070
MDA-MB-361 Ceritinib
10.0
ALK
RTK
-0.9910 0.89628
MDA-MB-361 Taselisib
10.0
PI3Ka, g, d
PI3K/mTOR
-0.9902 0.90326
MDA-MB-361 Cediranib
10.0
VEGFR/cKIT
RTK
-0.9803 0.88037
MDA-MB-361 Torin2
1.0
mTOR/ATM/ATR
PI3K/mTOR
-0.9642 0.85473
MDA-MB-361 Buparlisib
10.0
pan PI3K
PI3K/mTOR
-0.9584 0.84606
HCC1500 Ceritinib
10.0
ALK
RTK
-0.9535 0.74314
MDA-MB-134-VI Torin2
1.0
mTOR/ATM/ATR
PI3K/mTOR
-0.9461 0.64780
MDA-MB-134-VI Doxorubicin
3.1623
Chemo
Chemotherapy
-0.9458 0.69164
PDX1328 Ceritinib
10.0
ALK
RTK
-0.9426 0.68787
MDA-MB-361 Taselisib
3.1623
PI3Ka, g, d
PI3K/mTOR
-0.9425 0.82696
MDA-MB-361 Vorinostat
10.0
HDAC
Misc
-0.9392 0.81668
MDA-MB-361 Pictilisib
10.0
pan PI3K
PI3K/mTOR
-0.9375 0.80430
MDA-MB-157 Ceritinib
10.0
ALK
RTK
-0.9264 0.83901
PDX1328 Topotecan
10.0
Topo I
Chemotherapy
-0.9128 0.57713
MDA-MB-134-VI Doxorubicin
1.0
Chemo
Chemotherapy
-0.9124 0.57910
MDA-MB-157 Dinaciclib
1.0
pan CDK
Cell cycle
-0.9106 0.83515
HCC70 Dinaciclib
1.0
pan CDK
Cell cycle
-0.9093 0.74283
MDA-MB-157 Dinaciclib
0.31623
pan CDK
Cell cycle
-0.9006 0.83378
PDX1328 ABT-737
10.0
Bcl2/XL
Misc
-0.8967 0.69808
HCC70 Dinaciclib
0.1
pan CDK
Cell cycle
-0.8966 0.73612
MDA-MB-134-VI Topotecan
10.0
Topo I
Chemotherapy
-0.8909 0.42494
MDA-MB-361 Luminespib
1.0
HSP90
Misc
-0.8855 0.74897
  • Page 1 of 429
  • 1 to 25 of 10710 records